PSI Announces Expansion to India
Today, PSI CRO, a full-service contract research organization, announced their expansion to India and the appointment of Dr. Radhika Bobba as Regional Director for India and the Asia-Pacific region.
PSI CRO, a full-service contract research organization, announced their expansion to India.
PSI’s decision to conduct clinical trials in India was made based on requests from their clients. The PSI Indian base is serving as the hub for continuous expansion into the entire Asia-Pacific region.
About PSI CRO AG: PSI is a privately-held, full-service contract research organization (CRO), operating globally. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. PSI has exceptionally high repeat and referral business rates that are indicative of a commitment to be the best CRO in the world as measured by clients and employees. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
